We reviewed several topics relating to erectile dysfunction (ED) and its treatment, which are of interest to the community pharmacy. First, we analyze the community pharmacy's role as a center of health education to the population. Second, we discuss the legal aspects of medical prescription for drugs not financed by the Spanish National Health Service. Finally, we explain how community pharmacists may inform patients on the proper use of prescribed medicines for ED and any medications that may cause interactions or should be avoided with treatment.
It is highly unlikely for those affected by erectile dysfunction (ED) to ask questions at the community pharmacy, because this topic is often taboo and likely to cause embarrassment. This contrasts sharply with the usual behavior seen in the community pharmacy, where people freely ask anything that either directly, or indirectly, affects their health. It has also been noted that patients generally acquire their treatment for ED from community pharmacy locations far from their usual surroundings, and, even then, patients infrequently ask questions.
Nevertheless, we should take advantage of the potential that the community pharmacy has as an easily accessible center for patients to receive counseling about health topics. The simplest approach is to distribute educational and informative material that is rigorous, clearly written, and concise. This has been a valid approach with other medications and health topics, including the promotion of healthy living habits (quitting smoking, moderation in the consumption of alcohol, getting physical exercise appropriate for each age, and so on), recommendations for action in specific diseases (hypertension, diabetes, and so on), and institutional campaigns on the proper use of medicines. In the case of ED, this activity could consist of distributing reprints of the Document for the General Public (in this supplement) to community pharmacies.
The community pharmacy and drug prescriptions for ED All drugs currently indicated for treatment of ED (sildenafil, vardenafil, tadalafil, apomorphine, alprostadil [prostaglandin E l ], testosterone) may be dispensed only with a medical prescription.
The orally administered drugs sildenafil and apomorphine are not financed by the Spanish National Health System (NHS). Therefore, in the context of the NHS, the physician must prescribe them on the so-called 'form for prescription of medicines not financed by the National Health System,' colloquially known as the 'white prescription' (Table 1) . 1 Moreover, either in private care or in the NHS, prescriptions for these drugs require strict compliance with the law on medical prescriptions.
2 According to this law, there are two options for prescribing the medication that is not supported by the NHS.
Standard prescription
These prescriptions are usually valid for a single dispensation, which must be filled within 10 days of the date indicated on the prescription. One or more products may be listed on each prescription. Each prescription may include 1 or more containers of the product, although the amount corresponding to the purpose of the product or to a maximum of 3 months treatment may not be exceeded under any circumstances. After the medicine is dispensed, the prescription remains in the possession of the dispensing community pharmacist, who must keep it for 3 months. The disadvantage of this option is that it obliges the patient to purchase all the containers prescribed in a single total payment, an amount that the patient is not always able to afford.
Prescription for long-term treatments
In the case of prolonged treatments (called long-term treatments in the previously mentioned law), there is also the option of using a single prescription to obtain the medicine in several dispensations. In this case, the 10-day validity period of the prescription is calculated from the date indicated on the prescription to the first dispensation. The maximum validity period of the prescription is 3 months.
The prescribing physician should clearly indicate on the prescription the dispensing intervals as well as the number of containers that should be given on each dispensation.
Only 1 product may be listed on prescriptions for these treatments.
For these prolonged treatments, the community pharmacist must stamp, sign, and date each partial dispensation, indicating the amount of the partial dispensation and return the prescription to the patient. After the last dispensation has been made, the community pharmacist must retain the prescription and keep it for 3 months. It can be recommended that the pharmacist make a photocopy of the prescription to be kept in the community pharmacy records before returning it to the patient, or record the dispensation in the prescription book on a voluntary basis so that there is a record of divided dispensations in the community pharmacy (except in case of the last dispensation which will be as indicated above).
The community pharmacy as a patient information center on medicinal use
The dispensing of medicines is a professional act in which the community pharmacist, in addition to dispensing the medicines, informs patients about the medication they will be using while also collecting information to detect situations in which there may be problems related to the drugs prescribed.
Agents for the treatment of ED
To ensure proper use of the medicines, the community pharmacist should confirm that the patient has enough information about the treatment prescribed to him. Basically, the community pharmacist should ensure that the patient knows what the medicine is for, how it works, what effects it has on erections, how it should be taken, how often and for how long it should be taken. In addition, the community pharmacist should assess the information provided by the patient to avoid contraindication and to detect situations in which special caution should be taken with the use of the medication. The contraindications, precautions, and adverse reactions of the medicines indicated for ED are described in the core document. Finally, the community pharmacist should always offer to answer any questions the patient may have after reading the leaflets of the prescribed medicines.
Concomitant medications
The pharmacist should be alert to the use of any drug that may interact with ED treatment, and advise the patient to see his physician if any are detected. Simultaneous administration of sildenafil with nitrates or nitric oxide donors (eg, isosorbide dinitrate, molsidomine, isosorbide mononitrate, nicorandil, nitroglycerin, sodium nitroprusside) is absolutely contraindicated (Table 2) .
3-5 As its clearance is reduced when administered concomitantly with cytochrome P450 3A4 inhibitors (CYP3A4) (cimetidine, erythromycin, ketoconazole, itraconazole) and HIV protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir), sildenafil may interact with drugs that inhibit hepatic metabolism. Although an increased incidence of adverse events was not observed when sildenafil was administered concomitantly with CYP3A4 inhibitors, an initial dose of 25 mg should be considered in these patients. Concomitant administration of sildenafil with ritonavir, an HIV protease inhibitor that exhibits potent inhibitory action on cytochrome P450, is not recommended, and a maximum dose of 25 mg of sildenafil should not be exceeded in a 48-h period.
3,5 It is recommended that caution be taken when administering apomorphine to patients treated with nitrates (previously listed) because some patients have experienced vasovagal symptoms and significant resting blood pressure decreases when apomorphine was administered at higher than the recommended dose (5 mg).
3,6
Apomorphine should not be administered in combination with other centrally acting dopamine agonists (such as bromocriptine, lisuride, pergolide, pramipexole, ropinirole) or dopamine antagonists (such as sulpiride, thiapride, clozapine, olanzapine, quetiapine, haloperidol, zuclopentixol, metoclopramide, thioridazine, etc) because of the potential for pharmacodynamic interactions. Simultaneous intake of apomorphine and alcohol may cause an increase in the incidence and extent of hypotension. 3, 6 Patients treated with anticoagulants, such as heparin or warfarin, may be more prone to bleeding after the injection of alprostadil.
3
As an estimated 25% of ED cases have been related to the use of drugs, it is advisable for the community pharmacist to check whether the patient is under treatment with drugs that cause ED (see the core document).
3 If these problems are detected, the community pharmacist should refer the patient to the physician for reassessment of the patient's treatment.
Finally, because good control and treatment of other diseases such as diabetes mellitus or high blood pressure may contribute to worsening of ED, the community pharmacist should cooperate with the physician in the follow-up of treatment compliance in these patients.
